Company intelligence / Profile preview

Picodya

Rehovot, Central D., Israelpicodya.com ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Picodya has developed a fully automated, high-throughput diagnostic platform capable of running multiplexed molecular and immunoassays from various sample types with lab-quality results in near-patient settings. Proof-of-concept demonstrated for over forty biomarkers. U.S. expansion and collaborations with NIAID are underway.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceDiagnostic platform (molecular assays)Diagnostic platform (immunoassays)
Industry: Molecular Diagnostics

Partnerships

Collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on Picodya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picodya.

Explore the full profile